vesnarinone has been researched along with Experimental Hepatoma in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vesnarinone is an experimental drug which is known to inhibit TNF alpha release." | 1.30 | Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury. ( Baumann, H; Jacob, CO; Kambayashi, T; Lazarus, DD; Strassmann, G; Yato-Kioka, M, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lazarus, DD | 1 |
| Kambayashi, T | 1 |
| Yato-Kioka, M | 1 |
| Baumann, H | 1 |
| Jacob, CO | 1 |
| Strassmann, G | 1 |
1 other study available for vesnarinone and Experimental Hepatoma
| Article | Year |
|---|---|
Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury.
Topics: Acute-Phase Reaction; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Chemical and Drug Induce | 1997 |